J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B

BioPharma Dive

The buyout hands J J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.

pharminent June 8, 2026 (Last updated: June 8, 2026)

BioPharma Dive

The buyout hands J J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.

Related Stories